United States: California Supreme Court Details Antitrust Analysis Of "Reverse Payment" Patent Settlements

Last week, in In re Cipro Cases I & II, Case No. S198616, the Supreme Court of California adopted the United States Supreme Court's application of the Rule of Reason to the antitrust analysis of so-called "reverse payment" patent settlements (and rejected plaintiffs' arguments that settlement payments exceeding the costs of litigation or other services are per se unlawful), but also set forth a specific "structured" Rule of Reason analysis to be applied in analyzing such settlements.  A copy of the decision can be found here.

Reverse payment patent settlements

Under the Drug Price Competition & Patent Term Restoration Act of 1984 (also known as the Hatch-Waxman Act), codified as amended at 21 U.S.C. § 355, a prospective drug manufacturer may file a streamlined application with the Food and Drug Administration ("FDA") asserting a generic drug's bioequivalence with an existing pioneer drug.  The prospective generic manufacturer must file a certification regarding any patent bearing on the pioneer drug.  Under a so-called "paragraph IV" certification, the generic manufacturer can assert that the patent is invalid or will not be infringed by the proposed manufacture and sale of the generic drug.  21 § U.S.C. 355(j)(2)(A)(vii)(IV).

Submission of an application to manufacture a generic version of a pioneer drug covered by a patent is a technical act of infringement, and enables the pioneer manufacturer to file an infringement lawsuit.  The Hatch-Waxman Act provides somewhat unusual incentives (in the form of exclusive marketing and delayed follow-on generic application periods) to pioneer and first-to-file generic manufacturers.  "This legal regime means that, regardless of the degree of likely validity of a patent, the brand and first-filing generic have an incentive to effectively establish a cartel through a reverse payment settlement."  In re Cipro Cases I & II, Slip Op. at 9.  In a reverse payment patent settlement, the parties agree that (i) the generic will stay off the market until the expiration of the patent term and (ii) the pioneer will pay the generic some compensation.

History of the Cipro Cases

Bayer markets Cipro, a well-known antibiotic.  In 1987, Bayer was issued a U.S. patent on the active ingredient in Cipro.  In 1991, 12 years before the scheduled expiration of the patent, Barr Laboratories filed an application to market a generic version of Cipro, and included a paragraph IV certification that Bayer's patent was invalid and unenforceable.  Bayer sued Barr for patent infringement.  In 1997, the parties settled, agreeing that Barr would not market a generic version of Cipro prior to patent expiration.  In return, Bayer agreed to make payments to Barr and to supply it with Cipro for licensed resale beginning six months before patent expiration.  Pursuant to the settlement, between 1997 and 2003, Bayer paid Barr $398.1 million.

The settlement prompted numerous state and federal antitrust lawsuits.  The cases before the California Supreme Court arose from nine coordinated class action lawsuits in which indirect purchasers of Cipro alleged that the settlement violated the Cartwright Act (Cal. Bus. and Prof. Code §§ 16700, et seq.) as well as California's Unfair Competition Law (id., §§ 17200, et seq.) and common law prohibitions against monopolies.  The trial court and the California Court of Appeal held that because the settlement did not restrain competition longer than the exclusionary scope of the patent, it did not violate the Cartwright Act.  The California Supreme Court, in the first state supreme court decision concerning reverse payment patent settlements following the U.S. Supreme Court's decision in FTC v. Actavis, Inc., 133 S.Ct. 2223 (2013), reversed.

The California Supreme Court's application of FTC v. Actavis, Inc.

In Actavis, the U.S. Supreme Court reversed a federal decision applying the "scope of the patent test" and holding that Hatch-Waxman reverse payment settlement agreements are "immune from antitrust attack so long as [their] anticompetitive effects fall within the scope of the exclusionary potential of the patent."  Id. at 2227 (cit. omit.).  Instead, the Supreme Court held that such agreements should be evaluated under the Rule of Reason.  The California Supreme Court held that while Actavis "is not dispositive on matters of state law," In re Cipro Cases I & II, Slip Op. at 19, "[w]hat does affect the weight to be accorded Actavis is the extent to which its analysis establishes the metes and bounds of patent law and policy," because "[p]atent law is federal law."  Id.

In the California Supreme Court's view, "a critical insight undergirding Actavis is that patents are in a sense probabilistic, rather than ironclad: they grant their holders a potential but not certain right to exclude."  Id. at 20.  While patents are presumptively valid, they are issued in the first instance by the Patent Office in often short, ex parte proceedings.  Moreover, under principles of collateral estoppel, even a court determination of validity operates only on the parties and does not extend from one infringement case to the next.  Id. at 21.  While a court injunction excluding a competitor from the marketplace does not create an antitrust problem, "[w]ith a settlement, any restraint arises directly from the private agreement and only indirectly from the patent, which remains in the background, motivating the parties' actions according to their assessments of its strength."  Id. at 22.  "The scope of the patent test is flawed precisely because it assumes away whatever level of uncertainty a given patent . . . may be subject to."  Id.

Instead of applying the scope of the patent test, the proper question to ask is: "What would the state of competition have been without the agreement?  In the case of a reverse payment settlement, the relevant comparison is with the average level of competition that would have obtained absent settlement, i.e., if the parties had litigated validity/invalidity and infringement/noninfringement to a judicial determination."  Id. at 29.  "[T]he period of exclusion attributable to a patent is not its full life, but its expected life had enforcement been sought.  This expected life represents the baseline against which the competitive effects of any agreement must be measured."  Id. at 30.

The Court's analysis of reverse payment patent settlements – a "structured" Rule of Reason analysis

The California Supreme Court then determined that reverse payment patent settlements are to be evaluated under the Rule of Reason, and, unlike the U.S. Supreme Court in Actavis, set forth a particular "structured" version of Rule of Reason analysis to be applied to such settlements – which looks to four objective factors as possible surrogates for a direct investigation of the patent's strength.

To make out a prima facie case, a plaintiff must show (1) the settlement includes a limit on the settling generic challenger's entry into the market, (2) the settlement includes cash or equivalent financial consideration flowing from the brand to the generic challenger, and the consideration exceeds (3) the value of goods and services (other than any delay in market entry provided by the generic challenger to the brand) as well as (4) the brand's expected remaining litigation costs absent settlement.  Id. at 32.

The first two elements are self-explanatory.  The third element requires the plaintiff to establish that the consideration to the generic challenger exceeds the value of any other collateral products or services provided by the generic to the brand.  "Considerable caution is in order in evaluating settlements that include side agreements for generic products or services.  Historically, it appears brands and generics have engaged in business dealings outside the settlement context far less often than in it . . . . A side agreement involving difficult-to-value assets might conceivably be added to a patent settlement to provide cover for the purchase of additional freedom from competition."  Id. at 34.  Nevertheless, the Court may have left open a defense where, e.g., a brand manufacturer can choose any one of five companies to be a contract manufacturer, and chooses the patent suit defendant as part of a settlement.

The fourth element requires the plaintiff to establish that the amount of the payment, over and above the value of collateral products or services from the generic, also exceeds the brand's anticipated future litigation costs.  Id. at 35.  If the payment reflects traditional settlement considerations, such as avoided litigation costs or fair value for services, there is not the same concern that a patentee is using its monopoly profits to avoid the risk of patent invalidation or a finding of noninfringement.  Id., citing Actavis at 2236.

Although the plaintiff has the burden of proof on these four elements, because of defendants' superior knowledge, once the plaintiff has shown an agreement involving a reverse payment and a delay, the defendants have the burden of production to come forward with evidence of litigation costs and the value of collateral products and services that might explain the compensation.  (If the defendants fail to do so, the plaintiff has satisfied its burden on these points.  If the defendants do so, the plaintiff has the ultimate burden of persuasion that any reverse payment exceeds litigation costs and the value of collateral products or services.  In re Cipro Cases I & II, Slip Op. at 36.)

Once a plaintiff has made out a prima facie case that a reverse payment patent settlement has anticompetitive effects, the burden shifts to the defendants to offer legitimate justifications and come forward with evidence that the challenged settlement is in fact procompetitive.  Id. at 42.  The Court rejected plaintiffs' argument that every reverse payment in excess of litigation costs and collateral products and services is a per se violation of the Cartwright Act.  Id. at 43.  Although the Court did not specify what justifications may suffice, it did note that not "any justification will do.  An antitrust defendant cannot argue a settlement is procompetitive simply because it allows competition earlier than would have occurred if the brand had won the patent action . . . the relevant baseline is the average period of competition that would have obtained in the absence of settlement."  Id. at 43.

Finally, the plaintiff retains the ultimate burden to show that a challenged settlement is anticompetitive.  Id. at 45.  If a plaintiff makes out its prima facie case and can dispel each additional justification the defendants put forward to explain the consideration, "the conclusion follows that the settlement payment must include, in part, consideration for additional delay in entering the market.  That payment for delay is condemned by the Cartwright Act . . . ."  Id. at 45-46.  The Court applied the same reasoning to the plaintiffs' Unfair Competition Law and common law monopoly claims.  Id. at 51.

Conclusion

The California Supreme Court's decision in In re Cipro Cases I & II tracks the approach of the U.S. Supreme Court in Actavis, but somewhat uniquely sets forth a "structured" Rule of Reason analysis to reverse payment patent settlements that specifies the precise prima facie elements of a plaintiff's case, the defendants' possible defenses, and the relative burdens of persuasion and production.  The decision may increase the number of state court challenges to such settlements, while at the same time provide guidance to defendants about how to structure any defense.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
21 Nov 2018, Seminar, New York, United States

“Big data” is changing our economy. It has allowed Amazon, Google, Facebook and many others to redesign traditional business models and to create new or improved products and services with greater utility for consumers and often at very little cost.

24 Nov 2018, Speaking Engagement, New York, United States

Each year, the New York Region of IFA hosts a panel and reception at the NYU Law School. This year’s panel will include a discussion of the TCJA international provisions.

27 Nov 2018, Speaking Engagement, New York, United States

Employment Managing Associates, Alexandra Stathpoulos and Alexandra Heifetz are presenting at the University of California, Berkeley School of Law’s FORM+FUND Series.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions